Encouraging Preliminary Results in Myelofibrosis Trial Lead to Enhancements in Phase 2

Based on positive phase I data from the MANIFEST trial of BET inhibitor CPI-0610 as monotherapy and in combination with ruxolitinib in patients with myelofibrosis, phase II will stratify patients into three cohorts: transfusion and non-transfusion dependent patients and JAK1/2 inhibitor–naive patients.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.